InvestSMART

AFT Pharmaceuticals Limited (ASX: AFP) - Announcements

- Current share price for AFP : $3.870

ASX company news and announcements for AFT Pharmaceuticals Limited (AFP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AFT Pharmaceuticals Limited (AFP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AFT Pharmaceuticals Limited (AFP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AFT Pharmaceuticals Limited (AFP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$406 Letter to Shareholders 22 May 2019 7:30AM $2.400 $3.870 risen by 61.25%
$406 AFP results announcement May 22 2019 2 May 2019 7:31AM $1.930 $3.870 risen by 100.52%
$406 Clarification 23 Apr 2019 7:45AM $1.975 $3.870 risen by 95.95%
$406 AFT Pharmaceuticals completes another 3 deals 12 Apr 2019 9:10AM $1.975 $3.870 risen by 95.95%
$406 Transition to new NZX listing rules wef 1 April 2019 18 Mar 2019 7:32AM $1.975 $3.870 risen by 95.95%
$406 AFP Completes Successful Development of Maxigesic Rapid 1 Mar 2019 7:30AM $1.975 $3.870 risen by 95.95%
$406 2019 New Year Letter to Investors 20 Feb 2019 10:02AM $1.975 $3.870 risen by 95.95%
$406 Ongoing Disclosure Notice 14 Dec 2018 7:30AM $1.975 $3.870 risen by 95.95%
$406 New trial of MAXIGESIC pain relief published in major inter 3 Dec 2018 7:35AM $1.990 $3.870 risen by 94.47%
$406 Narrative correct on page 18 of the Interim Report 23 Nov 2018 9:29AM $1.990 $3.870 risen by 94.47%
$406 Half Yearly Report and Accounts 22 Nov 2018 7:31AM $1.990 $3.870 risen by 94.47%
$406 Half Yearly Report and Accounts 22 Nov 2018 7:30AM $1.990 $3.870 risen by 94.47%
$406 Half Yearly Report and Accounts 22 Nov 2018 7:30AM $1.990 $3.870 risen by 94.47%
$406 Half Yearly Report and Accounts 22 Nov 2018 7:30AM $1.990 $3.870 risen by 94.47%
$406 AFP starts to license Maxigesic IV with deal in South Korea 6 Nov 2018 7:30AM $2.050 $3.870 risen by 88.78%
$406 AFP to announce half year results on Thursday November 22 20 12 Oct 2018 7:31AM $2.050 $3.870 risen by 88.78%
$406 Maxigesic is now licensed in the Russian Federation 28 Sep 2018 8:30AM $2.000 $3.870 risen by 93.50%
$406 Change of Director's Interest Notice 22 Aug 2018 7:40AM $2.000 $3.870 risen by 93.50%
$406 Results of Meeting 3 Aug 2018 10:23AM $2.000 $3.870 risen by 93.50%
$406 AFT Annual Meeting 2018 Presentation 3 Aug 2018 8:15AM $2.000 $3.870 risen by 93.50%
$406 Chairman's Address to Shareholders 3 Aug 2018 8:14AM $2.000 $3.870 risen by 93.50%
$406 Shareholders meeting 2018 proxy 5 Jul 2018 7:31AM $2.000 $3.870 risen by 93.50%
$406 Notice of 2018 shareholders meeting 5 Jul 2018 7:31AM $2.000 $3.870 risen by 93.50%
$406 Annual Report FY2018 19 Jun 2018 7:32AM $2.000 $3.870 risen by 93.50%
$406 180615 7.12.1 Notice (2018 Options) 15 Jun 2018 3:12PM $2.000 $3.870 risen by 93.50%

326 - 350 of 546 results

Page 14 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.